The characteristics of upper airway edema in hereditary and acquired angioedema with C1-inhibitor deficiency
© 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology..
BACKGROUND: Angioedemas localized in the upper airway are potentially life threatening, and without proper treatment, they may lead to death by suffocation. Upper airway edemas (UAE) in bradykinin-mediated angioedemas can even be the first symptoms of the disease.
METHODS: Our survey was performed with a retrospective long-term follow-up method from the medical history of 197 hereditary (C1-INH-HAE) and 20 acquired C1-inhibitor deficiency (C1-INH-AAE), 3 factor XII and 3 plasminogen gene mutation (FXII-HAE, PLG-HAE) patients treated at our center between 1990 and 2020. The UAE group included edemas localized to the mesopharynx, hypopharynx, and larynx, as narrowing of these anatomical regions can lead to suffocation.
RESULTS: 98/197 C1-INH-HAE (47 families) and 13/20 C1-INH-AAE, 1/3 PLG-HAE, 1/3 FXII-HAE patients had experienced UAE at least once according to their medical history. In case of C1-INH-HAE patients, in 6/47 families who had undiagnosed ancestors had 13 members who died of suffocation. After the diagnosis, 1-1 member of two families died of UAE. 44/64 C1-INH-HAE patients did not smoke, 20/64 did. The occurrence of UAE was significantly higher in smoker patients. We analyzed 7607 HAE attacks of 56/98 patients. Out of all attacks, the incidence of UAE in the C1-INH-HAE group was 4%, and 9.5% in the C1-INH-AAE group, respectively.
CONCLUSION: Early diagnosis is key in bradykinin-mediated angioedemas cases, since the patient must be provided with adequate treatment; and also it is essential to inform patients about the importance of avoiding the trigger factors and the early symptoms of UAE, as these measures could significantly decrease the incidence of lethal UAEs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Clinical and translational allergy - 11(2021), 10 vom: 14. Dez., Seite e12083 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Balla, Zsuzsanna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 05.02.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/clt2.12083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334985609 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334985609 | ||
| 003 | DE-627 | ||
| 005 | 20231225224845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/clt2.12083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM334985609 | ||
| 035 | |a (NLM)34962723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Balla, Zsuzsanna |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The characteristics of upper airway edema in hereditary and acquired angioedema with C1-inhibitor deficiency |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. | ||
| 520 | |a BACKGROUND: Angioedemas localized in the upper airway are potentially life threatening, and without proper treatment, they may lead to death by suffocation. Upper airway edemas (UAE) in bradykinin-mediated angioedemas can even be the first symptoms of the disease | ||
| 520 | |a METHODS: Our survey was performed with a retrospective long-term follow-up method from the medical history of 197 hereditary (C1-INH-HAE) and 20 acquired C1-inhibitor deficiency (C1-INH-AAE), 3 factor XII and 3 plasminogen gene mutation (FXII-HAE, PLG-HAE) patients treated at our center between 1990 and 2020. The UAE group included edemas localized to the mesopharynx, hypopharynx, and larynx, as narrowing of these anatomical regions can lead to suffocation | ||
| 520 | |a RESULTS: 98/197 C1-INH-HAE (47 families) and 13/20 C1-INH-AAE, 1/3 PLG-HAE, 1/3 FXII-HAE patients had experienced UAE at least once according to their medical history. In case of C1-INH-HAE patients, in 6/47 families who had undiagnosed ancestors had 13 members who died of suffocation. After the diagnosis, 1-1 member of two families died of UAE. 44/64 C1-INH-HAE patients did not smoke, 20/64 did. The occurrence of UAE was significantly higher in smoker patients. We analyzed 7607 HAE attacks of 56/98 patients. Out of all attacks, the incidence of UAE in the C1-INH-HAE group was 4%, and 9.5% in the C1-INH-AAE group, respectively | ||
| 520 | |a CONCLUSION: Early diagnosis is key in bradykinin-mediated angioedemas cases, since the patient must be provided with adequate treatment; and also it is essential to inform patients about the importance of avoiding the trigger factors and the early symptoms of UAE, as these measures could significantly decrease the incidence of lethal UAEs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C1-inhibitor deficiency | |
| 650 | 4 | |a C1-inhibitor-Mangel | |
| 650 | 4 | |a acquired angioedema | |
| 650 | 4 | |a erbliches angioödem | |
| 650 | 4 | |a erworbenes angioödem | |
| 650 | 4 | |a hereditary angioedema | |
| 650 | 4 | |a kehlkopfödem | |
| 650 | 4 | |a laryngeal edema | |
| 650 | 4 | |a upper airway edema | |
| 650 | 4 | |a ödem der oberen atemwege | |
| 700 | 1 | |a Andrási, Noémi |e verfasserin |4 aut | |
| 700 | 1 | |a Pólai, Zsófia |e verfasserin |4 aut | |
| 700 | 1 | |a Visy, Beáta |e verfasserin |4 aut | |
| 700 | 1 | |a Czaller, Ibolya |e verfasserin |4 aut | |
| 700 | 1 | |a Temesszentandrási, György |e verfasserin |4 aut | |
| 700 | 1 | |a Csuka, Dorottya |e verfasserin |4 aut | |
| 700 | 1 | |a Varga, Lilian |e verfasserin |4 aut | |
| 700 | 1 | |a Farkas, Henriette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational allergy |d 2011 |g 11(2021), 10 vom: 14. Dez., Seite e12083 |w (DE-627)NLM216124530 |x 2045-7022 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:10 |g day:14 |g month:12 |g pages:e12083 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/clt2.12083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 10 |b 14 |c 12 |h e12083 | ||